Kamada begins Phase I/II trial of Glassia to treat graft-versus-host disease

Israel-based Kamada has initiated a US-based proof-of-concept (POC) trial with its proprietary, highly-purified, liquid form of human Alpha-1 Antitrypsin (AAT) 'Glassia' for the treatment of graft-versus-host disease (GVHD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news